Insmed chair and CEO Lewis sells $1.6m in stock
#Insmed #William Lewis #Insider Trading #Stock Sale #Biotech #NASDAQ:INSM #Brinsuppi #Earnings Report
📌 Key Takeaways
- William Lewis sold $1.6 million worth of Insmed stock while exercising options to acquire additional shares
- Insmed's stock has surged nearly 99% over the past year, with analysts considering it potentially overvalued
- The company reported mixed Q4 2025 earnings with revenue beating expectations but EPS falling short
- Insmed provided 2026 revenue guidance projecting over $1 billion in sales for its Brinsuppi product
- Analysts maintain generally positive ratings for the company despite the insider selling
📖 Full Retelling
🏷️ Themes
Insider Trading, Biotech Performance, Market Analysis
📚 Related People & Topics
Insider trading
Trading using nonpublic information
# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...
Biotechnology
Use of living systems and organisms to develop or make useful products
Biotechnology is a multidisciplinary field that involves the integration of natural sciences and engineering sciences in order to achieve the application of organisms and parts thereof for products and services. Specialists in the field are known as biotechnologists. The term biotechnology was first...
William Lewis
Topics referred to by the same term
# William Lewis **William Lewis** or **Willie Lewis** may refer to: ### Politics and Law * **William Lewis (judge) (1752–1819):** U.S. federal judge and legal scholar from Pennsylvania. * **William J. Lewis (1766–1828):** U.S. Representative from Virginia. * **William Lewis (Welsh politician...
Entity Intersection Graph
Connections for Insider trading:
Deep Analysis
Why It Matters
The sale of $1.6 million in stock by Insmed's Chair and CEO is significant as it represents a major transaction by a key insider during a period of substantial stock price appreciation. Investors often monitor such sales closely for signals about executive confidence in the company's future prospects, especially when the stock has nearly doubled in the past year.
Context & Background
- Insmed is a biotech company with a market cap of $34.3 billion
- The company's stock has surged nearly 99% over the past year
- CEO William Lewis exercised options to acquire shares on the same day as the sale
- Insmed recently provided 2026 revenue guidance projecting over $1 billion in sales for Brinsupri
What Happens Next
Investors will likely scrutinize future SEC filings for any additional insider trading activity to gauge management sentiment. Market attention will remain focused on Insmed's ability to meet its ambitious 2026 revenue guidance for Brinsupri, which will be a key factor for the stock's performance.
Frequently Asked Questions
William Lewis sold 11,099 shares of Insmed common stock.
The sales occurred at prices ranging from $149.17 to $153.38 per share.
Yes, following these transactions, Lewis directly owns 301,185 shares and indirectly owns additional shares through family trusts.